ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Targeting ferroptosis by trimetazidine and probiotics to attenuate 5-fluorouracil-induced intestinal mucositis in mice.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal mucositis is a common side effect in cancer patients receiving chemotherapy, yet effective treatment options are lacking. This study aimed to investigate the potential protective effects of trimetazidine and probiotics combination in a 5-FU-induced intestinal mucositis model. We hypothesized that these agents would attenuate mucositis through anti-inflammatory and antioxidant effects associated with modulation of ferroptosis-related pathways, particularly through Nrf2-associated regulatory mechanisms. 5-fluorouracil in a dose of 50 mg/kg/day i.p. for 6 consecutive days starting from the 11th to the 16th day for induction of chemotherapy-induced intestinal mucositis (CIM) and mice were divided into five equal groups as follows: control group, untreated group, trimetazidine group, probiotics group, and trimetazidine + probiotics group. The effects of these drugs on inflammation, oxidative stress, and ferroptosis were assessed. Treatment with trimetazidine and probiotics in combination produced further improvement in disease activity, reflected by increased body weight and reduced diarrhea scores. Significant reductions were observed in IL-1β and MDA levels, with parallel increases in SOD, GPx4, CAT, Nrf2, and SLC7A11. The combination also provided additional improvement in intestinal structure (villus height, crypt depth, and enteritis score) compared with each monotherapy group. Either trimetazidine or probiotics alleviated 5-FU-induced intestinal mucositis and might be considered promising candidates for preventing CIM by anti-inflammatory, antioxidant, and mechanisms associated with modulation of ferroptosis-related pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.